Curated News
By: NewsRamp Editorial Staff
May 12, 2025
Oragenics to Host Webinar on Concussion Treatment and Lead Candidate ONP-002
TLDR
- Oragenics (NYSE American: OGEN) is hosting a management update webinar discussing its lead candidate for concussion treatment, providing early access advantage for investors.
- Oragenics focuses on nasal delivery of pharmaceutical medications in neurology. The lead candidate, ONP-002, in Phase IIa trial targets mild traumatic brain injury.
- Oragenics' intranasal therapy for concussion treatment aims to reduce brain inflammation and swelling, offering hope for improved care and outcomes in traumatic brain injuries.
- Oragenics' webinar presents a breakthrough in concussion treatment with promising preclinical results, highlighting the potential of ONP-002 in addressing brain injuries.
Impact - Why it Matters
This news matters as it provides insights into a potential breakthrough therapy for mild traumatic brain injury, highlighting Oragenics' innovative approach to addressing a critical medical need. Investors and individuals interested in neurology and infectious diseases can gain valuable information about the company's developments and future prospects.
Summary
Oragenics (NYSE American: OGEN) will host a management update webinar to discuss the unmet medical need in concussion treatment and its lead candidate, ONP-002, a Phase IIa therapy for mild traumatic brain injury. Key presenters include CEO Janet Huffman, CMO Dr. James Kelly, and Chief Clinical Officer Dr. Frank Peacock.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Oragenics to Host Webinar on Concussion Treatment and Lead Candidate ONP-002
